Enanta Pharmaceuticals has initiated a Phase II clinical trial for the treatment of community-acquired pneumonia in the United States and Canada for EDP-420, an investigational bridged bicyclic macrolide antibiotic for the treatment of community-acquired respiratory tract infections.
In the Pipeline
- Enanta Pharmaceuticals has initiated a Phase II clinical trial for the treatment of community-acquired pneumonia in the United States and Canada for EDP-420, an investigational bridged bicyclic macrolide antibiotic for the treatment of community-acquired respiratory tract infections.
- Nuvelo has been granted fast-track designation by the FDA for its lead product candidate, alfimeprase, for the treatment of acute peripheral arterial occlusion.
- Genta has announced that the first patient has been entered into a new clinical study that will evaluate the bioactivity and safety of the company’s lead anticancer drug, oblimersen sodium (Genasense) injection, administered by intermittent subcutaneous injection.
- EntreMed has initiated Phase II studies with MKC-1, a novel, orally active, small molecule cell cycle inhibitor with a unique mechanism of action. Patients with advanced or metastatic breast cancer who have failed conventional therapies are expected to be enrolled.
- BioMarin Pharmaceutical has announced that the FDA has granted fast-track designation for sapropterin dihydrochloride (Phenoptin) for phenylketonuria.
- Affymax has initiated a Phase II clinical trial of Hematide, a synthetic peptide-based erythropoiesis-stimulating agent, to treat anemia in cancer patients.
- Schering-Plough reported that the FDA has granted fast designation to its investigational oral hepatitis C protease inhibitor (SCH 503034), currently in Phase II clinical development for the treatment of chronic hepatitis C virus infection.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.